Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from____ to ____ Commission File Number: 001-32295 FENNEC PHARMACEUTICALS INC. OR (Exact Name of Registrant as Specified in Its Charter) | British Co ...

Fennec Pharmaceuticals (FENC) Q2 2025 Earnings Call August 14, 2025 08:30 AM ET Speaker0Good morning, ladies and gentlemen, and welcome to the Fintech Pharmaceuticals Second Quarter twenty twenty five Earnings and Corporate Update Conference Call. At this time, all participants are in a listen only mode. Later, we will conduct a question and answer session and instructions on how to participate will be given at that time. As a reminder, today's conference is being recorded. Now I would like to turn the conf ...

Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.2 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -83.33%. A quarter ago, it was expected that this company would post a loss of $0.12 per share when it actually produced a loss of $0.04, delivering a surprise of +66.67%.Over the last four quarters, the company ...

Core Insights - Fennec Pharmaceuticals reported total net revenues of $9.7 million for Q2 2025, reflecting a 33% increase compared to the same quarter in 2024, driven by growth in large community practices and academic centers [1][3][9] - The company has seen a successful uptake of its product PEDMARQSI in the UK and Germany, with plans for additional EU launches [1][3] - The management anticipates results from a clinical trial in Japan (STS-J01) in the second half of 2025, which may lead to registration and potential licensing opportunities [1][3] Financial Performance - Net product sales for Q2 2025 were approximately $9.7 million, up from $7.3 million in Q2 2024, attributed to growth in the adolescent and young adult (AYA) population [9][11] - Selling and marketing expenses decreased to $4.4 million in Q2 2025 from $4.6 million in Q2 2024, while general and administrative expenses increased slightly to $7.0 million from $6.9 million [9][11] - The company reported a net loss of $3.2 million for Q2 2025, compared to a net loss of $5.6 million in Q2 2024 [11] Business Highlights - Fennec's segmentation model and data-driven targeting have led to significant growth in both new and repeat customers, particularly in large community and academic practices [6] - A large national oncology group has added PEDMARK to its formulary for patients under 40, indicating growing recognition of the need to protect younger patients from cisplatin-induced hearing loss [6] - The NCODA PQI issued for PEDMARK aims to provide clinical data and guidance for healthcare professionals managing patients on cancer therapies [6] Upcoming Events - Fennec will ring the NASDAQ closing bell on September 5, 2025, alongside PEDMARK patients and their families [10] - The company will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City [10] Product Information - PEDMARK is the first FDA-approved therapy to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients [15][19] - The product has received Orphan Drug Exclusivity in the U.S. and is commercially available in the U.K. and Germany under the brand name PEDMARQSI [28][30]

Core Viewpoint - The article emphasizes the importance of confirming the sustainability of stock trends for profitable short-term investing, highlighting the need for sound fundamentals and positive earnings estimates to maintain momentum. Group 1: Trend Analysis - The trend in short-term investing is crucial, as it can lead to significant profits if sustained [1] - A common issue is that trends may reverse before trades are exited, resulting in capital losses [2] - Investors can utilize the "Recent Price Strength" screen to identify stocks on an uptrend supported by strong fundamentals [3] Group 2: Stock Example - Adherex Technologies Inc. (FENC) - FENC has shown a solid price increase of 68.7% over the past 12 weeks, indicating strong investor interest [4] - The stock has also increased by 7.6% over the last four weeks, suggesting that the upward trend is still intact [5] - FENC is trading at 90.5% of its 52-week high-low range, indicating a potential breakout [5] Group 3: Fundamental Strength - FENC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [6] - The Zacks Rank system has a strong track record, with Rank 1 stocks averaging a +25% annual return since 1988 [7] - The Average Broker Recommendation for FENC is 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term performance [7] Group 4: Additional Opportunities - Besides FENC, there are other stocks that meet the criteria of the "Recent Price Strength" screen, suggesting further investment opportunities [8] - The article encourages exploring over 45 Zacks Premium Screens tailored to different investing styles for potential winning stock picks [8]

Fennec Pharmaceuticals (FENC) FY 2025 Conference May 20, 2025 03:00 PM ET Speaker0 Hello, and welcome to the latest in our series of fireside chats here at H. C. Wainwright's Bioconnet Conference at NASDAQ. My name is Ram Selvaraju and I'm a Senior Healthcare Equity Research Analyst and Managing Director within Wainwright's Equity Research Department. I'm joined here today by members of the senior executive leadership team at FENEC Pharmaceuticals. FENEC is traded on the NASDAQ under the ticker symbol FENEC ...

Table of Contents OR UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from____ to ____ Commission File Number: 001-32295 FENNEC PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in Its Charter) | British C ...

Fennec Pharmaceuticals (FENC) Q1 2025 Earnings Call May 13, 2025 08:30 AM ET Company Participants Robert Andrade - Chief Financial OfficerJeffrey Hackman - CEO & Member of the Board of DirectorsSudan Loganathan - Managing DirectorRaghuram Selvaraju - Managing Director, Healthcare Equity Research Conference Call Participants Chase Knickerbocker - Senior Equity Research Analyst - HealthcareMichael Okunewitch - Senior Biotechnology Analyst Operator Good morning, ladies and gentlemen, and welcome to FENIC Pharm ...

Fennec Pharmaceuticals (FENC) Q1 2025 Earnings Call May 13, 2025 08:30 AM ET Speaker0 Good morning, ladies and gentlemen, and welcome to FENIC Pharmaceuticals First Quarter twenty twenty five Earnings and Corporate Update Conference Call. At this time, all participants are in a listen only mode. Later, we will conduct a question and answer session and instructions on how to participate will be given at that time. As a reminder, today's conference call is being recorded. Now, I would like to turn the confere ...

Financial Performance - Adherex Technologies Inc. reported a quarterly loss of $0.04 per share, better than the Zacks Consensus Estimate of a loss of $0.12, representing an earnings surprise of 66.67% [1] - The company posted revenues of $8.75 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 9.32%, but down from $25.38 million year-over-year [2] - Over the last four quarters, the company has only surpassed consensus EPS estimates once [2] Market Performance - Adherex Technologies shares have declined approximately 0.8% since the beginning of the year, compared to a decline of 0.6% for the S&P 500 [3] - The company's current consensus EPS estimate for the upcoming quarter is -$0.10 on revenues of $9.44 million, and for the current fiscal year, it is $0.03 on revenues of $54.54 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Adherex Technologies belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that the company's stock may outperform the market based on current estimates [5][6]